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Background: White matter lesions (WML) are a risk factor
for Alzheimer’s disease. Progression of WML is associated
with vascular factors and cognitive decline in population
based studies but the course of WML is unknown in
Alzheimer’s disease.
Objective: To investigate the prevalence and risk factors for
progression of WML in Alzheimer’s disease.
Subjects: 38 patients with Alzheimer’s disease for whom
blood pressure measurements and sequential brain MRIs
were available.
Methods: The proportion of patients with progression of
WML was calculated, stratified on baseline absence or
presence of WML by analysis of variance. Odds ratios (OR)
were calculated by age and sex adjusted logistic regression
to quantify the relation between blood pressure and
progression of WML.
Results: About 25% of the patients showed progression of
WML. Patients with WML at baseline had significantly more
progression than those without WML at baseline (adjusted
mean difference = 1.2; 95% confidence interval (CI), 0.6 to
1.8). Diastolic blood pressure (DBP) was particularly related
to progression of WML (OR=5.9 (95% CI, 1.0 to 37.6) per
10 mm Hg DBP, p = 0.05).
Conclusions: Alzheimer’s disease patients with WML at
baseline are at risk for rapid progression of WML. WML
may offer a potential treatment target in this disease to
ameliorate the rate of cognitive decline.
T
here is evidence that subcortical vascular white matter
lesions (WML) result in an increased risk for Alzheimer’s
disease.1 In population based studies, individuals with
progression of WML experience a steeper decline in cognition
than those without. Identification of progression of WML in
the course of Alzheimer’s disease would provide further
evidence for a causal role for vascular factors in this disorder.
However, neither the degree of progression of WML nor the
identification of risk factors for progression have yet been
studied in this disease. Proof of progression would offer the
possibility of identifying a subpopulation of Alzheimer
patients in whom further cognitive decline may be amelio-
rated by treatment of a potentially modifiable vascular risk
factor. With this in mind we set out to investigate the
prevalence and risk factors of progression of WML in
Alzheimer’s disease.
METHODS
In the study period, 268 consecutive patients were seen at the
Alzheimer Centre of the VU Medical Centre, Amsterdam,
with ‘‘probable’’ Alzheimer’s disease according to the
NINCDS-ADRDA criteria. Of these, 38 had sequential brain
magnetic resonance imaging (MRI), with an initial scan as
part of a routine diagnostic procedure (baseline) and a follow
up scan as part of a routine outpatient follow up. These 38
patients formed the study group. The mean follow up period
was 2.2 years (range 1.0 to 5.1), and did not differ between
those with and without progression of white matter lesions.
All patients were examined using a fluid attenuated
inversion recovery (FLAIR) pulse sequence on a 1.0 T scanner
(Impact, Siemens, Erhlangen, Germany). WML were rated
using the age related white matter changes (ARWMC) rating
scale.2 Briefly, WML were rated on a four point scale (0–3) in
five regions in the left and right hemisphere separately,
leading to an ARWMC sum score (range 0–30). Baseline and
follow up scans were rated independently, blinded for scan
order and clinical data. Intrarater studies on a random
sample of 32 of the 38 scans showed good to excellent
agreement (k=0.6 to 1.0).
Blood pressure was measured with a mercury sphygmo-
manometer and with the participant in a sitting position after
at least five minutes of rest. Self reported or informant report
on smoking behaviour (ever/never) was recorded from the
patient’s clinical history. Diabetes mellitus was considered to
be present if the participant was taking glucose lowering
drugs or if the random glucose was higher than 11.1 mmol/l.
Global cognitive function was assessed by the mini-mental
state examination (MMSE).
Progression of WML was defined as an increase of one
point or more on the ARWMC scale between baseline and
follow up (fig 1). We calculated the proportion of patients
with progression of WML stratified on sex and on baseline
absence or presence of WML by analysis of variance
(ANOVA). In addition we calculated the mean diastolic and
systolic blood pressure (DBP and SBP) in patients with or
without progression of WML by ANOVA. We calculated odds
ratios (OR) by age and sex adjusted logistic regression to
quantify the relation between blood pressure and the
progression of WML. Additional adjustments were made for
possible confounding factors, including smoking (ever/
never), diabetes mellitus (yes/no), and global cognitive
function.
RESULTS
Patients with a follow up scan were older than those without
(mean (SD) age, 72.2 (9.4) years v 65.9 (8.8) years (p,0.05)).
Mean MMSE score at baseline was 21.4. Other baseline
characteristics are presented in table 1. Except for age, there
were no differences in baseline characteristics between those
with or without follow up MRI.
Mean ARWMC score was 0.8 at baseline (median 0;
interquartile range 0 to 0.25) and 1.5 during follow up
Abbreviations: ARWMC, age related white matter changes rating
scale; MMSE, mini-mental state examination; NINCDS-ADRDA,
National Institute of Neurological and Communicative Disorders–
Alzheimer’s Disease and Related Disorders Association; WML, white
matter lesion
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(median 0; interquartile range 0 to 1.25). About 25% of the
patients showed progression of WML. The relative risk of age
for progression of WML was 1.2 per year (95% confidence
interval (CI), 1.1 to 1.5). Men had more progression of WML
than women (30.0% v 16.7%, p=0.34), especially above 70
years (55.6% v 40.0%, p=0.02). Patients with WML at
baseline had significantly more progression of WML than
those without (adjusted mean difference in ARWMC score
1.2 (95% CI, 0.6 to 1.8); p,0.05). Patients with progression
had a higher DBP than those without (92.9 (14.9) v 82.8
(11.1) mm Hg (p=0.05)). This was not true for SBP.
The relative risk of baseline SBP for progression of WML
was 1.6 per 10 mm Hg increase in blood pressure (95% CI, 0.9
to 2.8) (p=0.12) and the relative risk of baseline DBP was
5.9 (1.0 to 37.6) (p=0.05). Adjustment for confounding
factors did not alter the magnitude of the association.
DISCUSSION
Our study shows that over the relatively short period of two
years WML load doubled in a sample of typical Alzheimer’s
disease patients. The risk of progression was influenced by
age, sex, baseline ARWMC score, and DBP.
Selection bias may have influenced our findings. As blood
pressure is the most important risk factor for WML3 it is
possible that patients with the highest degree of WML were
unable to visit an outpatient clinic any more—for example
because of gait disturbances.4 However, this selection bias
presumably only played a role in patients with the most
severe WML and hypertension; thus this form of bias may
even have underestimated progression of WML. Because only
single blood pressure measurements were available to us,
misclassification of blood pressure might have occurred;
however, as these measurements were done without prior
notice of the neuroimaging findings, any misclassification
would have been random and not related to the outcome. As
such, it might even have diluted (underestimated) the effects
that we found.
Figure 1 Axial (transverse) slices at four different sections of the brain at baseline (upper panel; mean age related white matter changes rating scale
(ARWMC) score = 1) and during follow up (lower panel; mean ARWMC score = 5) in a 79 year old male patient with Alzheimer’s disease and
progression of white matter lesions (WML). Arrows indicate some examples of emergence or progression of WML.
Table 1 Characteristics of the study population at
baseline, with or without serial magnetic resonance
imaging
Characteristic With follow up
Without
follow up
Number of subjects 38 230
Age at baseline (years) 65.9 (8.8) 72.3 (9.7)*
Women 47.4% 60.9%
Mean duration of follow up (years;
range) 2.2 (1.0 to 5.1) na
Mean ARWMC baseline (range) 0.8 (0 to 8) 1.8 (3.7)
Mean ARWMC follow up 1.5 (0 to 17) na
Hypertension 78.4% 57.2%
Systolic blood pressure (mm Hg) 149.5 (25.8) 150.5 (21.9)
Diastolic blood pressure (mm Hg) 85.3 (12.3) 86.0 (10.5)
Diabetes 0 9.4%
Smoking (ever) 32.1% 37.8%
MMSE 21.4 (4.6) 19.7 (5.3)
Values are age and sex adjusted means (SD) or percentages unless stated
otherwise.
*p,0.05 (analysis of covariance).
ARWMC, age related white matter changes rating scale; MMSE, mini-
mental state examination; na, not applicable.
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We measured WML using the ARWMC scale, which is an
ordinal scale with a predefined maximum score. This may
limit the detectability of changes in WML: the change has to
be of a certain magnitude in order to result in a one point
increase on the ARWMC scale; furthermore, this scale has a
ceiling effect, in contrast to volumetric methods. This type of
measurement error is most likely to have affected those
patients with the highest degree of WML, presumably even
leading to an underestimation of the relative risk of blood
pressure on the progression of WML.
Our findings suggest that Alzheimer’s disease patients with
WML at baseline are at risk for rapid progression of WML.
This is in line with findings from population based studies.5
They may therefore be at increased risk of progressive
cognitive decline compared with patients without baseline
WML. If these findings are substantiated, it could indicate
that further cognitive decline in Alzheimer patients might be
ameliorated by modifying the progression of WML—for
example by treating hypertension. Future studies should
address whether progression of WML coincides with cogni-
tive decline, and whether an intervention can modify this
favourably.6
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